American Century Companies Inc. Sells 2,696 Shares of Guardant Health, Inc. (NASDAQ:GH)

American Century Companies Inc. decreased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,924 shares of the company’s stock after selling 2,696 shares during the quarter. American Century Companies Inc. owned about 0.08% of Guardant Health worth $3,175,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. R Squared Ltd acquired a new stake in Guardant Health in the 4th quarter valued at $26,000. SBI Securities Co. Ltd. bought a new position in shares of Guardant Health in the fourth quarter valued at $43,000. Kimelman & Baird LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at about $58,000. Quantbot Technologies LP bought a new stake in shares of Guardant Health during the fourth quarter worth about $80,000. Finally, Jones Financial Companies Lllp raised its holdings in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GH shares. Stephens reiterated an “overweight” rating and set a $55.00 price target on shares of Guardant Health in a research note on Wednesday, March 26th. Guggenheim reaffirmed a “buy” rating and set a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Piper Sandler increased their price target on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Stifel Nicolaus raised their price objective on Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, Raymond James reiterated an “outperform” rating and issued a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $48.95.

Guardant Health Stock Down 3.4 %

GH opened at $40.58 on Monday. The business’s fifty day simple moving average is $44.39 and its 200 day simple moving average is $34.96. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The stock has a market cap of $5.01 billion, a PE ratio of -11.40 and a beta of 1.45.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.